denoemagene deradenovec — Full data
Q4 2026
We expect to present one-year Cohort 2 data and two-year Cohort 1 data from MyPEAK-1 in the fourth quarter of 2026.Source filing
TNYA biotech catalysts & pipeline
TENAYA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
denoemagene deradenovec — Regulatory decision
Q4 2026
The company plans to provide an update on the status of these discussions in the fourth quarter of 2026.Source filing
TN-401 — Interim data
Q4 2026
We expect to present interim Cohort 2 results in the fourth quarter of the year.Source filing
TN-401 — Regulatory decision
Q4 2026
Tenaya is currently engaging with regulators on late-stage pivotal trial planning for TN-401 and plans to provide an update on the status of its discussions in the fourth quarter of 2026.Source filing